Hims & Hers Health, Inc. (HIMS) Bundle
Understanding Hims & Hers Health, Inc. (HIMS) Revenue Streams
Revenue Analysis
According to the Q3 2023 financial report, the company reported $159.7 million in total revenue, representing a 4.3% year-over-year growth.
| Revenue Stream | Q3 2023 Revenue | Percentage of Total Revenue |
|---|---|---|
| Telehealth Services | $86.3 million | 54.0% |
| Prescription Medications | $45.2 million | 28.3% |
| Consumer Products | $28.2 million | 17.7% |
Key revenue insights for the fiscal year 2023 include:
- Total annual revenue reached $638.5 million
- Telehealth segment grew by 12.6% compared to previous year
- Prescription medication revenue increased 7.8% year-over-year
Geographic revenue breakdown shows 92% of revenue generated within the United States market.
| Region | Revenue Contribution |
|---|---|
| United States | $587.4 million |
| International Markets | $51.1 million |
A Deep Dive into Hims & Hers Health, Inc. (HIMS) Profitability
Profitability Metrics
Financial performance analysis reveals critical insights into the company's profitability landscape.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 76.5% | 74.2% |
| Operating Profit Margin | -15.3% | -22.7% |
| Net Profit Margin | -16.8% | -25.4% |
Key profitability observations include:
- Revenue for 2023: $385.2 million
- Gross profit: $294.8 million
- Operating expenses: $230.5 million
| Efficiency Metric | 2023 Performance |
|---|---|
| Cost of Revenue | $90.4 million |
| Sales & Marketing Expense | $198.3 million |
| Research & Development | $32.2 million |
Debt vs. Equity: How Hims & Hers Health, Inc. (HIMS) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital allocation strategy.
| Debt Metric | Amount ($ Millions) |
|---|---|
| Total Long-Term Debt | $98.4 million |
| Short-Term Debt | $22.6 million |
| Total Debt | $121 million |
| Debt-to-Equity Ratio | 1.45 |
Key debt financing characteristics include:
- Credit Rating: B+ from Standard & Poor's
- Interest Rates: Ranging between 6.5% - 8.2%
- Debt Maturity Profile: Predominantly 3-5 year terms
Equity funding details demonstrate strategic capital management:
| Equity Component | Amount ($ Millions) |
|---|---|
| Total Shareholders' Equity | $83.6 million |
| Common Stock Outstanding | 187.3 million shares |
| Market Capitalization | $1.2 billion |
Recent financing activities highlight balanced capital strategy with 65% equity and 35% debt composition.
Assessing Hims & Hers Health, Inc. (HIMS) Liquidity
Liquidity and Solvency Analysis
As of Q4 2023, the company's financial liquidity metrics reveal critical insights for potential investors.
Liquidity Ratios
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 1.23 | 2023 |
| Quick Ratio | 0.89 | 2023 |
Working Capital Trends
Working capital position for the fiscal year 2023 was $42.6 million, representing a 15.3% increase from the previous year.
Cash Flow Analysis
| Cash Flow Category | Amount | Year |
|---|---|---|
| Operating Cash Flow | $18.3 million | 2023 |
| Investing Cash Flow | -$22.7 million | 2023 |
| Financing Cash Flow | $12.5 million | 2023 |
Liquidity Strengths
- Positive operating cash flow of $18.3 million
- Increased working capital by 15.3%
- Current ratio above 1.0, indicating short-term solvency
Potential Liquidity Concerns
- Quick ratio below 1.0 at 0.89
- Negative investing cash flow of $22.7 million
Is Hims & Hers Health, Inc. (HIMS) Overvalued or Undervalued?
Valuation Analysis: Is the Company Overvalued or Undervalued?
As of February 2024, the company's financial valuation metrics reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -14.52 |
| Price-to-Book (P/B) Ratio | 3.68 |
| Enterprise Value/EBITDA | -11.23 |
| Current Stock Price | $4.87 |
Stock price performance analysis for the past 12 months demonstrates significant volatility:
- 52-week low: $2.65
- 52-week high: $7.39
- Total stock price decline: 34.2%
Analyst recommendations provide additional perspective:
| Recommendation | Percentage |
|---|---|
| Buy | 45% |
| Hold | 35% |
| Sell | 20% |
Dividend metrics indicate no current dividend distribution.
Key Risks Facing Hims & Hers Health, Inc. (HIMS)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Competitive Landscape Risks
| Risk Category | Potential Impact | Current Market Position |
|---|---|---|
| Digital Health Competition | Market share erosion | $500 million total addressable market |
| Telehealth Services | Pricing pressure | 15% market penetration |
Regulatory and Compliance Risks
- FDA regulatory compliance challenges
- Potential changes in telehealth reimbursement policies
- State-level licensing restrictions
Financial Risk Indicators
| Financial Metric | 2023 Value | Risk Level |
|---|---|---|
| Cash Burn Rate | $42 million per quarter | High |
| Debt-to-Equity Ratio | 1.2 | Moderate |
Operational Risks
- Technology infrastructure vulnerabilities
- Patient data privacy concerns
- Supply chain disruptions for prescription medications
Key external risks include 36% potential market volatility and increasing healthcare technology competition.
Future Growth Prospects for Hims & Hers Health, Inc. (HIMS)
Growth Opportunities
The company's growth strategy focuses on several key drivers and market opportunities:
- Total addressable market for telehealth estimated at $250 billion by 2025
- Digital health market projected to reach $639.4 billion globally by 2026
- Telemental health services expected to grow at 23.7% CAGR through 2028
| Growth Metric | 2023 Value | 2024 Projection |
|---|---|---|
| Revenue Growth | $385.9 million | $455-$475 million |
| Customer Acquisition | 1.6 million active subscribers | 1.9-2.1 million projected |
| Product Line Expansion | 7 therapeutic categories | 9-10 planned categories |
Strategic expansion initiatives include:
- International market penetration in Canada and potential European markets
- Continued investment in $15 million annual R&D
- Potential strategic acquisitions in complementary digital health sectors
Key competitive advantages:
- Proprietary technology platform
- Direct-to-consumer digital health model
- Scalable technology infrastructure
Hims & Hers Health, Inc. (HIMS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.